Tom Vanden Berghe

Expert in Cell death and Disease

[Tom Vanden Berghe @TomVBerghe]

📰 New paper alert!
In case you missed it over the holidays: my News & Views on the latest work from the Linkermann Lab is out. https://t.co/5rbQPIRfkg
Congrats to the Linkermann team on this exciting study! 🎉
#ScienceTwitter #CellDeath #Research @Nature
https://t.co/WO9mvtmNhh

[Tom Vanden Berghe @TomVBerghe]

@eikan_em @Linkermann_Lab Strong story with impact. Top!

[Tom Vanden Berghe @TomVBerghe]

Game changer in translational ferroptosis research. Check out this nature paper by Linkermann lab and his amazing team ! Oestrogen defends against kidney damage caused by iron-dependent cell death https://t.co/WO9mvtmNhh

[Tom Vanden Berghe @TomVBerghe]

Mads Daugaard is striking again. High level of translational oncology presented @EWCD meeting in Fiuggi Italy.

[ECDO @ECDOorg]

Registration for ECDO2025 is now officially open. Secure your place at the legendary event in Berlin today

https://t.co/ib8ZfyHWFB

[ECDO @ECDOorg]

⚡️SAVE the DATE!!!! SAVE the DATE!!!!⚡️

[BMC Biology @BMCBiology]

Harnessing ferroptosis for precision oncology: challenges and prospects.

New #openaccess Review from Fernández-Acosta @TomVBerghe and co as part of our ‘#Ferroptosis’ Collection

https://t.co/ptWWwNPbXP

[The PhD Place @ThePhDPlace]

This is such an accurate representation of being a PhD student

[Fabio Martinon @fabiomartinon]

🚀 Exciting opportunity! 🎓 The PhD program in Cancer and Immunology in Lausanne is accepting applications! If you're passionate about advancing research in cancer or immunology, we want to hear from you! 🌟 #PhD #CancerResearch #Immunology https://t.co/o4VYUw0oyS via @unil

[Tom Vanden Berghe @TomVBerghe]

@bruno_de_geest Interesting. Can you send me pdf?

[Tom Vanden Berghe @TomVBerghe]

Knappe koppen https://t.co/RGipRZYDRX Don't forget to watch tonight! Niet vergeten kijken deze avond.

[Eric Topol @EricTopol]

The human proteomic revolution proceeds with high-throughput assessment, AI analytics, correlation with health and disease, drug interactions, biomarkers
https://t.co/VsYD6vGxXp

[Harvey J. Berger, M.D. @harveyjberger]

While at @DanaFarber, Brian Bruker (now @OHSUKnight) started the personalized medicine revolution with the first targeted cancer drug, imatinib. The first of a series of BCR-ABL inhibitors that made Ph+ #CML a chronic disease. A transformative discovery.

[Tom Vanden Berghe @TomVBerghe]

Interested in our work? Watch 'Knappe koppen' on national TV VRT1 Wednesday Dec 4 at 21h35. Geinteresseerd in ons werk? Kijk 'knappe koppen' op VRT1 woensdag 4 dec 21h35
https://t.co/YRtD63kUgz

[Tom Vanden Berghe @TomVBerghe]

Another memorable CSHA ferroptosis meeting in Suzhou China. Thx to organisers and cell death community! @CSHANews #ferroptosis

[Tom Vanden Berghe @TomVBerghe]

Big congrats to Geraldine Veeckmans for poster price award ⁦@CSHANews⁩. Let’s translate ferroptosis inhibitors to clinic! ⁦@FWOVlaanderen⁩ #ferroptosis

[The Conrad Lab @Conrad_Lab]

Very cool - congratulations! First ferroptosis conference in the 🇺🇸 Looking forward to it!

[Tom Vanden Berghe @TomVBerghe]

@Conrad_Lab @bstockwell Really pity I had to miss this memorable moment. Major achievement to be proud of. Congrats to both of you

[Tom Vanden Berghe @TomVBerghe]

@ECDOorg @bstockwell @cddpress Congrats Brent. Major achievement. Pity I missed it due to emergency surgery to my back. @bstockwell

[Nieves Peltzer @PeltzerNieves]

Cell Death-Related Ubiquitin Modifications in Inflammatory Syndromes: From Mice to Men https://t.co/OJMRzj24JL #mdpibiomedicines via @Biomed_MDPI